Phenytoin Antibody (304): sc-57974

Phenytoin Antibody (304) is a mouse monoclonal IgG1 antibody that detects Phenytoin in non-species reactive applications by enzyme-linked immunosorbent assay (ELISA). Phenytoin (304) antibody is available in a non-conjugated form, making it suitable for various experimental setups. Phenytoin, a widely used antiepileptic drug, plays a crucial role in managing seizures by stabilizing neuronal membranes in the motor cortex. Phenytoin achieves this by inhibiting voltage-gated sodium channels, which helps to prevent excessive neuronal firing that can lead to seizures. Phenytoin′s function lies in maintaining a balance in neuronal excitability, thereby providing therapeutic benefits for patients with epilepsy. Additionally, Phenytoin undergoes significant post-translational modifications, including glucuronidation, which affects pharmacokinetics and bioavailability. These modifications are essential for drug metabolism and elimination, influencing both efficacy and safety profile. Understanding the dynamics of Phenytoin′s action and metabolic pathways is vital for optimizing treatment regimens and minimizing adverse effects, such as sedation and gingival hyperplasia, which can arise from prolonged use.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Phenytoin Antibody (304) References:

1. Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs.  |  DeToledo, JC. and Ramsay, RE. 2000. Drug Saf. 22: 459-66. PMID: 10877039
2. Ciprofloxacin-phenytoin interaction.  |  Dillard, ML., et al. 1992. Ann Pharmacother. 26: 263. PMID: 1554944
3. Subacute phenytoin intoxication syndrome.  |  Tindall, RS. and Willerson, J. 1978. Arch Intern Med. 138: 1168-9. PMID: 208480
4. Decreased phenytoin levels in patients receiving chemotherapy.  |  Grossman, SA., et al. 1989. Am J Med. 87: 505-10. PMID: 2683764
5. Phenytoin-induced thrombocytopenia.  |  Brown, JJ. and Chun, RW. 1986. Pediatr Neurol. 2: 99-101. PMID: 3150279
6. [Interaction of Phenytoin with Enteral Formulas, Proteins, and Dietary Fiber in Vitro and in Vivo].  |  Kuwabara, N., et al. 2023. Yakugaku Zasshi. 143: 85-94. PMID: 36596543
7. Bioavailability of phenytoin: clinical pharmacokinetic and therapeutic implications.  |  Neuvonen, PJ. 1979. Clin Pharmacokinet. 4: 91-103. PMID: 378503
8. Phenytoin hypersensitivity.  |  Josephs, SH., et al. 1980. J Allergy Clin Immunol. 66: 166-72. PMID: 7400479
9. Phenytoin-salicylate interaction.  |  Leonard, RF., et al. 1981. Clin Pharmacol Ther. 29: 56-60. PMID: 7460475
10. Fosphenytoin: a novel phenytoin prodrug.  |  Boucher, BA. 1996. Pharmacotherapy. 16: 777-91. PMID: 8888074